Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and Sezary syndrome: Interim results of a multicenter Phase 1 trial

著录项

• 来源
  《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2018年第2018期|共1页
• 作者

  Querfeld Christiane; Thompson John A.; Taylor Matthew; Pillai Raju; Johnson Lisa D. S.; Catalano Tina; Petrova Penka S.; Uger Bob A.; Irwin Meghan; Thompson Theresa; Sievers Eric L.; Akilov Oleg;

  展开▼
• 作者单位

  City Hope Natl Med Ctr Duarte CA USA;

  Univ Washington SCCA Seattle WA 98195 USA;

  Oregon Hlth &

  Sci Univ Portland OR 97201 USA;

  City Hope Natl Med Ctr Duarte CA USA;

  Trillium Therapeut Mississauga ON Canada;

  Trillium Therapeut Mississauga ON Canada;

  Trillium Therapeut Mississauga ON Canada;

  Trillium Therapeut Mississauga ON Canada;

  Trillium Therapeut Mississauga ON Canada;

  Trillium Therapeut Mississauga ON Canada;

  Trillium Therapeut Mississauga ON Canada;

  Univ Pittsburgh Med Ctr Pittsburgh PA USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 肿瘤学;
• 关键词